Skip to main content

Advertisement

SpringerLink
Log in

Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin

  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

Introduction Several epidemiologic studies have provided suggestive evidence of a link between coetaneous malignant melanoma (CMM) and breast cancer. The Breast Cancer Linkage Consortium (BCLC) reported approximately 2.6-fold increase in the risk for CMM among BRCA2 carrier families. Methods To evaluate the role of BRCA1/2 mutations in CMM, we screened 92 Jewish patients of Ashkenazi origin diagnosed with CMM for the three Ashkenazi founder mutations: 185delAG and 5382insC in the BRCA1 and 6174delT in the BRCA2 gene. Information about personal demography, family history of cancer, and occupational and lifestyle history was collected. Results Thirty-seven of 92 (40.2%) CMM patients reported a family history of cancer in a first-degree relative. In 14 patients, history of breast cancer (BC) was recorded; however, no family had features associated with BRCA carrier status (i.e., young age at BC onset, history of several BC cases or ovarian cancer in the family). None of the patients were found to carry any of these three mutations. Conclusion Our results suggest a limited role for the three Ashkenazi BRCA founder mutations in CMM risk among the Ashkenazi Jewish population. Therefore, screening patients with CMM for these BRCA1/2 mutations is not warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stahl S, Bar-Meir E, Friedman E et al (2004) Genetics of melanoma. Isr Med Assoc J 6:774–777

    PubMed  Google Scholar 

  2. The Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310–1316. doi:10.1093/jnci/91.15.1310

    Article  Google Scholar 

  3. Easton DF, Steele L, Fields P et al (1997) Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12–13. Am J Hum Genet 61:120–128. doi:10.1086/513891

    Article  PubMed  CAS  Google Scholar 

  4. Brose MS, Rebbeck TR, Calzone KA et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365–1372

    PubMed  CAS  Google Scholar 

  5. Thompson D, Easton DF (2002) The Breast Cancer Linkage Consortium cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365

    PubMed  CAS  Google Scholar 

  6. Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408. doi:10.1056/NEJM199705153362001

    Article  PubMed  CAS  Google Scholar 

  7. Begg CB (2002) On the use of familial aggregation in population based case probands for calculating penetrance. J Natl Cancer Inst 94:1221–1226

    PubMed  Google Scholar 

  8. Gruber SB, Petersen GM (2002) Cancer risks in BRCA1 carriers: time for the next generation of studies. J Natl Cancer Inst 94:1344–1345

    PubMed  Google Scholar 

  9. Niell BL, Rennert G, Bonner JD et al (2004) BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 96:15–21

    Article  PubMed  CAS  Google Scholar 

  10. Yossepowitch O, Olvera N, Satagopan JM et al (2003) BRCA1 and BRCA2 germline mutations in lymphoma patients. Leuk Lymphoma 44:127–131. doi:10.1080/1042819021000040332

    Article  PubMed  CAS  Google Scholar 

  11. Hubert A, Peretz T, Manor O et al (1999) The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 65:921–924. doi:10.1086/302525

    Article  PubMed  CAS  Google Scholar 

  12. Phelan CM, Kwan E, Jack E et al (2002) A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. Hum Mutat 20:352–357. doi:10.1002/humu.10123

    Article  PubMed  CAS  Google Scholar 

  13. Iscovich J, Abdulrazik M, Cour C et al (2002) Prevalence of BRCA2 6174delT mutation in Israeli uveal melanoma patients. Int J Cancer 98:42–44. doi:10.1002/ijc.10155

    Article  PubMed  CAS  Google Scholar 

  14. Hearle N, Damato BE, Humphreys J et al (2003) Contribution of germline mutations in BRCA2, P16 (INK4A), P14 (ARF) and P15 to uveal melanoma. Invest Ophthalmol Vis Sci 44:458–462. doi:10.1167/iovs.02-0026

    Article  PubMed  Google Scholar 

  15. Landi MT, Goldstein AM, Tsang S et al (2004) Genetic susceptibility in familial melanoma from northeastern Italy. J Med Genet 41:557–566. doi:10.1136/jmg.2003.016907

    Article  PubMed  CAS  Google Scholar 

  16. Goggins W, Gao W, Tsao H (2004) Association between female breast cancer and cutaneous melanoma. Int J Cancer 111:792–794. doi:10.1002/ijc.20322

    Article  PubMed  CAS  Google Scholar 

  17. Hemminki K, Vaittinen P, Easton D (2000) Familial cancer risks to offspring from mothers with 2 primary breast cancers: leads to cancer syndromes. Int J Cancer 88:87–91. doi:10.1002/1097-0215(20001001)88:1 ≤ 87::AID-IJC14 ≥ 3.0.CO;2-F

    Article  PubMed  CAS  Google Scholar 

  18. Evans HS, Lewis CM, Robinson D et al (2001) Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility. Int J Cancer 94:758–759. doi:10.1002/ijc.1534

    Article  PubMed  CAS  Google Scholar 

  19. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ et al, Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON) (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42:711–719 doi: 10.1136/jmg.2004.028829

    Google Scholar 

  20. Lubinski J, Phelan CM, Ghadirian P et al (2004) Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer 3:1–10. doi:10.1023/B:FAME.0000026816.32400.45

    Article  PubMed  CAS  Google Scholar 

  21. Kadouri L, Easton DF, Edwards S et al (2001) CAG and GGC repeat polymorphism in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer 85:36–40. doi:10.1054/bjoc.2001.1777

    Article  PubMed  CAS  Google Scholar 

  22. Kadouri L, Kote-Jarai Z, Hubert A et al (2004) A single nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 but not in BRCA1 carriers or non-carriers. Br J Cancer 90:2002–2005. doi:10.1038/sj.bjc.6601837

    Article  PubMed  CAS  Google Scholar 

  23. Kadouri L, Kote-Jarai Z, Easton EF et al (2004) Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers. Int J Cancer 108:399–403. doi:10.1002/ijc.11531

    Article  PubMed  CAS  Google Scholar 

  24. Wang SC, Makino K, Su LK, Pao AY, Kim JS, Hung MC (2001) Ultraviolet irradiation induces BRCA2 protein depletion through a p53-independent and protein synthesis-dependent pathway. Cancer Res 61:2838–2842

    PubMed  CAS  Google Scholar 

  25. Galper S, Gelman R, Recht A, Silver B, Kohli A, Wong JS et al (2002) Second non-breast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 52:406–414. doi:10.1016/S0360-3016(01)02661-X

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sharett Institute of Oncology, Hebrew University-Hadassah Medical Center, Jerusalem, 91120, Israel

    Luna Kadouri, Mark Temper, Tal Grenader, Tamar Hamburger, Tamar Peretz & Michal Lotem

  2. Human Genetic Laboratories, Hebrew University-Hadassah Medical Center, Jerusalem, Israel

    Dvorah Abeliovich

Authors
  1. Luna Kadouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Temper
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tal Grenader
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dvorah Abeliovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tamar Hamburger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tamar Peretz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Michal Lotem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luna Kadouri.

Additional information

Dr. Mark Temper is an equal contributor to the manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kadouri, L., Temper, M., Grenader, T. et al. Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin. Familial Cancer 8, 29–32 (2009). https://doi.org/10.1007/s10689-008-9206-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-008-9206-8

Keywords

Search

Navigation